Get 50% OFF This Monsoon!
Indrayani Biotech
No Data Available
No Stocks
Unlock Smart Score
See Detailed Analysis & Insights
Unlock Insights
See Detailed Analysis & Insights
No Research Report
ROE
Avg ROE (3 Yrs) : NaN%
ROCE
Avg ROCE (3 Yrs) : NaN%
ROA
Avg ROA (3 Yrs) : NaN%
NPM
Avg NPM (3 Yrs) : NaN%
No Data Available
Unlock Management Data
See Detailed Analysis & Insights
Indrayani Biotech Limited was incorporated in 1992. The Company came out with a public issue in 1994 to part-finance its project to produce cut flowers, strawberries, tissue culture plantlets and hybrid vegetable seeds. Presently, the Company is engaged in manufacture of electric motors, generators, transformers and electricity distribution and control apparatus
Technical agreements have been signed with Floral Max, Malaysia; for rose cultivation; and with B L McKenzie and Associates, New Zealand, for tissue culture. The planting material for strawberries has been acquired from the US. The company has signed a test agreement with the Technology Transfer Offer of the University of California to obtain certified planting material from nurseries in California.
IBL started exporting flowers to Holland and Dubai during 1994-95. Restricted water supply and changes in ecology resulted in a shortfall in achieving its goals.
In 1995-96, the company incurred losses due to reasons beyond the control of the management like insufficient water supply, labour problem and sub-standard infrastructure. To overcome the above problems, the company is considering to shift its green houses to alternate locations.
During the year 2010-11, the Scheme of Arrangement, seeking to reduce the equity share capital of the Company by 88%, conversion of unsecured loan into the equity shares, demerging the entire business into Indrayani Tissue Culture Pvt. Ltd., merging YoGoYo Division of Websource Technologies Ltd., was effective from August 21, 2010. Similarly, the Scheme of Arrangement for Amalgamation of Helios Solutions Limited and A-Diet Express Hospitality Services Limited as a going concern with the Company was made effective from April 1, 2018.
IBL Investments Ltd was incorporated as wholly owned subsidiary company in 2022-23; Dindigul Farm Product Pvt Ltd became subsidiary in 2022-23.
Indrayani Biotech share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.
Market capitalization of Indrayani Biotech indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Indrayani Biotech is valued compared to its competitors.
Indrayani Biotech PE ratio helps investors understand what is the market value of each stock compared to Indrayani Biotech 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.
The PEG ratio of Indrayani Biotech evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.
Return on Equity (ROE) measures how effectively Indrayani Biotech generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.
Return on Capital Employed (ROCE) evaluates the profitability of Indrayani Biotech in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.
Total debt of Indrayani Biotech shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.
The Debt-to-Equity (DE) ratio of Indrayani Biotech compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.
CAGR shows the consistent growth rate of Indrayani Biotech over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.
Technical analysis of Indrayani Biotech helps investors get an insight into when they can enter or exit the stock. Key components of Indrayani Biotech Technical Analysis include:
There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.
There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Indrayani Biotech shares often struggle to rise above due to selling pressure.
Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Indrayani Biotech ’s financial health and profitability.
Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.
Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.
The financials of Indrayani Biotech provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.
The profit and loss statement of Indrayani Biotech highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Indrayani Biotech .
The balance sheet presents a snapshot of Indrayani Biotech ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.
Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.